Latest period
$857.50M
YoY change
+18.9%
5Y CAGR
+7.9%
Peak year (2023)
$926.40M
Cumulative CapEx
$7.82B
CapEx history chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
Latest: $898.40M
CapEx growth chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
Latest: +18.9%
CapEx history table for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
| 2025 | $898.40M | +18.9% | +$142.50M | ||
| 2024 | $755.90M | -18.4% | −$170.50M | ||
| 2023 | $926.40M | +57.0% | +$336.30M | ||
| 2022 | $590.10M | +6.9% | +$38.20M | ||
| 2021 | $551.90M | -10.2% | −$62.70M | ||
| 2020 | $614.60M | +43.1% | +$185.00M | ||
| 2019 | $429.60M | +12.1% | +$46.50M | ||
| 2018 | $383.10M | +40.5% | +$110.50M | ||
| 2017 | $272.60M | -46.7% | −$239.30M | ||
| 2016 | $511.90M | -24.5% | −$166.03M | ||
| 2015 | $677.93M | +103.6% | +$344.93M | ||
| 2014 | $333.01M | +113.0% | +$176.68M | ||
| 2013 | $156.32M | +216.8% | +$106.99M | ||
| 2012 | $49.34M | -13.8% | −$7.88M | ||
| 2011 | $57.22M | -42.6% | −$42.47M | ||
| 2010 | $99.69M | +2.4% | +$2.37M | ||
| 2009 | $97.32M | +179.2% | +$62.46M | ||
| 2008 | $34.86M | +89.0% | +$16.41M | ||
| 2007 | $18.45M | +556.2% | +$15.63M | ||
| 2006 | $2.81M | -43.4% | −$2.15M | ||
| 2005 | $4.96M | -19.6% | −$1.21M | ||
| 2004 | $6.17M | -79.2% | −$23.48M | ||
| 2003 | $29.66M | -13.7% | −$4.71M | ||
| 2002 | $34.37M | +318.0% | +$26.15M | ||
| 2001 | $8.22M | +26.6% | +$1.73M | ||
| 2000 | $6.50M | +13.9% | +$795.00K | ||
| 1999 | $5.70M | +90.0% | +$2.70M | ||
| 1998 | $3.00M | +42.9% | +$900.00K | ||
| 1997 | $2.10M | -75.6% | −$6.50M | ||
| 1996 | $8.60M | +160.6% | +$5.30M | ||
| 1995 | $3.30M | -52.2% | −$3.60M | ||
| 1994 | $6.90M | -32.4% | −$3.30M | ||
| 1993 | $10.20M | +385.7% | +$8.10M | ||
| 1992 | $2.10M | +110.0% | +$1.10M | ||
| 1991 | $1.00M | — | — |
- 2025$898.40M+18.9%
- 2024$755.90M-18.4%
- 2023$926.40M+57.0%
- 2022$590.10M+6.9%
- 2021$551.90M-10.2%
- 2020$614.60M+43.1%
- 2019$429.60M+12.1%
- 2018$383.10M+40.5%
- 2017$272.60M-46.7%
- 2016$511.90M-24.5%
- 2015$677.93M+103.6%
- 2014$333.01M+113.0%
- 2013$156.32M+216.8%
- 2012$49.34M-13.8%
- 2011$57.22M-42.6%
- 2010$99.69M+2.4%
- 2009$97.32M+179.2%
- 2008$34.86M+89.0%
- 2007$18.45M+556.2%
- 2006$2.81M-43.4%
- 2005$4.96M-19.6%
- 2004$6.17M-79.2%
- 2003$29.66M-13.7%
- 2002$34.37M+318.0%
- 2001$8.22M+26.6%
- 2000$6.50M+13.9%
- 1999$5.70M+90.0%
- 1998$3.00M+42.9%
- 1997$2.10M-75.6%
- 1996$8.60M+160.6%
- 1995$3.30M-52.2%
- 1994$6.90M-32.4%
- 1993$10.20M+385.7%
- 1992$2.10M+110.0%
- 1991$1.00M—
CapEx values are taken from Regeneron Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current CapEx (TTM) is $857.50M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Regeneron Pharmaceuticals (REGN) most recent annual CapEx stands at $898.40M (2025) – grew 18.9% year-over-year.
Regeneron Pharmaceuticals CapEx compound annual growth for the 2020–2025 (5 years) window is +7.9%, with mixed annual results across the window.
Regeneron Pharmaceuticals CapEx edged down from $926.40M in 2023 to $898.40M in 2025, a 3.0% drawdown.
Across the available history, CapEx reached its high of $926.40M in 2023 and its low of $1.00M in 1991.
Regeneron Pharmaceuticals Capital Expenditures by Year
Regeneron Pharmaceuticals Capital Expenditures 2025: $898.40M
In 2025, Regeneron Pharmaceuticals reported CapEx of $898.40M, grew 18.9% from 2024.
Regeneron Pharmaceuticals Capital Expenditures 2024: $755.90M
Regeneron Pharmaceuticals CapEx in 2024 was $755.90M, declined 18.4% below 2023.
Regeneron Pharmaceuticals Capital Expenditures 2023: $926.40M
2023's CapEx for Regeneron Pharmaceuticals came in at $926.40M, surged 57.0% from 2022. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Capital Expenditures 2022: $590.10M
Regeneron Pharmaceuticals posted CapEx of $590.10M in 2022, grew 6.9% from 2021.
Regeneron Pharmaceuticals Capital Expenditures 2021: $551.90M
Regeneron Pharmaceuticals CapEx in 2021 was $551.90M.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by CapEx
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation